Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)
暂无分享,去创建一个
A. d’Arminio Monforte | F. Bai | G. Marchetti | F. Castelli | M. Puoti | P. Morelli | A. Cascio | A. Cattelan | E. di Meco | G. Rizzardini | A. Saracino | M. Rizzi | G. Migliorino | B. Menzaghi | M. Moioli | F. Tordato | C. Aldieri | F. Borghi | E. Van Hauwermeiren | Francesca Raumer
[1] G. Keating,et al. Dalbavancin , 2021, Reactions Weekly.
[2] E. Poeschla,et al. Advantages of Outpatient Treatment with Long‐Acting Lipoglycopeptides for Serious Gram‐Positive Infections: A Review , 2020, Pharmacotherapy.
[3] J. Strymish,et al. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: a case report. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[4] F. Segala,et al. Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection , 2019, Infection.
[5] T. Walsh,et al. Dalbavancin Reduces Hospital Stay and Improves Productivity for Patients with Acute Bacterial Skin and Skin Structure Infections: The ENHANCE Trial , 2019, Infectious Diseases and Therapy.
[6] M. Wilke,et al. Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment – a health economic analysis using German DRG data , 2019, GMS infectious diseases.
[7] M. M. Morán Rodríguez,et al. Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study , 2019, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
[8] J. Miro,et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci , 2019, Annals of Clinical Microbiology and Antimicrobials.
[9] S. Warren,et al. Dalbavancin to Treat Infected Massive Endoprostheses: A Case Report and Cost Comparison Analysis , 2019, Journal of bone and joint infection.
[10] F. Thalhammer,et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection , 2019, Infection.
[11] A. Mehta,et al. Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report , 2019, Open forum infectious diseases.
[12] F. Tumietto,et al. Clinical experience with dalbavancin for the treatment of deep sternal wound infection. , 2019, Journal of global antimicrobial resistance.
[13] P. Delobel,et al. French national cohort of first use of dalbavancin: a high proportion of off-label use. , 2019, International journal of antimicrobial agents.
[14] James S. Lewis,et al. Dalbavancin use in an academic medical center and associated cost-savings. , 2019, International journal of antimicrobial agents.
[15] Mitulkumar A. Patel,et al. Dalbavancin Use in the Emergency Department Setting , 2019, The Annals of pharmacotherapy.
[16] B. Gilliam,et al. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections , 2019, Infectious Diseases and Therapy.
[17] G. Weiss,et al. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[18] Y. Golan. Current Treatment Options for Acute Skin and Skin-structure Infections , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] Á. Soriano,et al. Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections , 2019, Antimicrobial Agents and Chemotherapy.
[20] K. Kaye,et al. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility. , 2019, Diagnostic microbiology and infectious disease.
[21] R. Harrington,et al. Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population , 2019, Open forum infectious diseases.
[22] A. Jandourek,et al. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety , 2018, Open forum infectious diseases.
[23] F. Thalhammer,et al. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis , 2018, Emerging Microbes & Infections.
[24] F. Thalhammer,et al. Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] Á. Soriano,et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. , 2017, International journal of antimicrobial agents.
[26] M. Bassetti,et al. The role of dalbavancin in skin and soft tissue infections , 2018, Current opinion in infectious diseases.
[27] O. Murillo,et al. [Analysis of dalbavancin in animal models]. , 2017, Enfermedades infecciosas y microbiologia clinica.
[28] F. Thalhammer,et al. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) , 2016, European Journal of Clinical Microbiology & Infectious Diseases.
[29] Kimberly D. Leuthner,et al. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) , 2016, Therapeutics and clinical risk management.
[30] Y. Carmeli,et al. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis. , 2016, The Journal of antimicrobial chemotherapy.
[31] D. Krievins,et al. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] M. Wilcox,et al. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies , 2015, Drug Safety.
[33] J. Baldassarre,et al. Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue , 2015, Antimicrobial Agents and Chemotherapy.
[34] T. Rosen,et al. Dalbavancin (Dalvance) for the treatment of acute bacterial skin infection. , 2014, Skinmed.
[35] A. Friedrich,et al. Systematic literature analysis and review of targeted preventive measures to limit healthcare-associated infections by meticillin-resistant Staphylococcus aureus. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[36] Jan V Hirschmann,et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] M. Wilcox,et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. , 2014, The New England journal of medicine.
[38] M. Zervos,et al. Dalbavancin: a novel antimicrobial , 2007, International journal of clinical practice.
[39] W. O'Riordan,et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] Patchen Dellinger,et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] A. Gottlieb,et al. Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers , 2004, Antimicrobial Agents and Chemotherapy.
[42] B. Goldstein,et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.